

THYROID CANCER UPDATE 2025

AGENDA

OTOLARYNGOLOGY ROUNDS 2025 | ROUND 2

Saturday, 15 November 2025 | VIRTUAL

Time	Topic	Speaker
12:25-12:55	Opening Countdown	
12:55-13:00	Introduction	Dr. Samer El-Kaissi Dr. Mahdi Shkoukani
MODULE 1:		Moderator: Dr. Samer El-Kaissi / Dr. Mahdi Shkoukani
13:00-13:20	Active Surveillance for Papillary Thyroid Microcarcinoma	Dr. Yasuhiro Ito
13:20-13:40	Hemithyroidectomy for Non-Hereditary Medullary Thyroid Carcinoma	Dr. Yasuhiro Ito
13:40-14:00	Radioactive Iodine & Risk of Secondary Malignancies	Dr. Cari Kitahara
14:00-15:00	Panel Discussion and Q&A	Dr. Aly Bernard Dr. Hammad Hussain Dr. Juan Pablo Pantoja Dr. Mazin Merdad Dr. Naveed Ahmed Dr. Yasir Elhassan Dr. Yogesh More
MODULE 2:		Moderator: Dr. Samer El-Kaissi / Dr. Mahdi Shkoukani
15:00-15:20	ATA Thyroid Nodule Guidelines 2025 Preview	Dr. Trevor Angell
15:20-15:40	ATA 2025 Guidelines on Differentiated Thyroid Cancer: What's New?	Dr. Marika Russell
15:40-16:00	Break	

Disclosure and Conflict of Interest

The planning committee, faculty, and others in control of content (either individually or as a group) have disclosed relevant financial relationships with ineligible companies.

All relevant financial relationships have been reviewed and mitigated in accordance with ACCME standards

THYROID CANCER UPDATE 2025

AGENDA

OTOLARYNGOLOGY ROUNDS 2025 | ROUND 2

Saturday, 15 November 2025 | VIRTUAL

Time	Topic	Speaker
MODULE 3: Moderator: Dr. Samer El-Kaissi / Dr. Mahdi Shkoukani		
16:00-16:30	Keynote Lecture: Neoadjuvant Treatment of Thyroid Cancer	Dr. Gregory Randolph
16:30-18:00	Tumour Board	Dr. Ahmad Matakah Dr. Balaji Balasubramanian Dr. Basel Altrabulsi Dr. Christian Nasr Dr. Eiman Alseddeeqi Dr. Hidayath Ali Ansari Dr. Hussain Alsaffar Dr. Joseph Scharpf Dr. Marika Russell Dr. Mario Skugor Dr. Trevor Angell
18:00-18:05	Closing Remarks	

Disclosure and Conflict of Interest

The planning committee, faculty, and others in control of content (either individually or as a group) have disclosed relevant financial relationships with ineligible companies.

All relevant financial relationships have been reviewed and mitigated in accordance with ACCME standards